Regulatory authorities emphasize integrated control strategies, but CAR-T specification setting requires balancing data rigor with regulatory flexibility.
TMO heads into Q4 earnings with Specialty Diagnostics growth, fresh FDA approvals and launches that could lift results on Jan. 29.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback